Articles related to PSYCHOPHARMACOLOGY

Viral claims described the ketogenic diet as a cure for schizophrenia despite limited supporting evidence. Available research consists of small pilot studies, while established treatment approaches continue to rely on pharmacologic and psychosocial interventions.

Sedative-hypnotic drug effects vary with meal timing, metabolism, and drug half-life in patients with insomnia. These pharmacologic factors influence sleep onset and maintenance, particularly in patients with psychiatric comorbidities requiring concurrent medications.

The FDA granted Fast Track designation to elunetirom, an oral CNS thyroid hormone receptor agonist, for adjunctive treatment of bipolar depression, while the agent remains in a 30-participant open-label phase 2 trial with no human efficacy data yet available.

A single 25-mg dose of synthetic psilocybin with structured psychological support produced rapid, large-magnitude reductions in suicidal ideation through 12 weeks in 20 treatment-resistant adults with major depressive disorder, with two participants experiencing worsening ideation.

Adjunctive low-dose naltrexone did not separate from placebo on depressive symptom reduction in a 38-patient randomized trial of adults with moderate major depressive disorder on existing antidepressants.

A JAMA Psychiatry network meta-analysis ranked lumateperone highest for efficacy and aripiprazole highest for acceptability among five FDA-approved adjunctive atypical antipsychotics for major depressive disorder.